November 22, 2005 -- Wyeth said that Effexor is now an approved treatment for panic disorder; Pain Therapeutics took a big hit after Oxytrex failed to meet its endpoint of reducing physical dependency; ADML, which develops tests for early cancer detection, will buy two Chinese companies for 13.2 million shares of stock; NicOx of France said that Pfizer selected a drug candidate from its partnership portfolio, triggering a 2 million euro milestone; Myriad Genetics will extend its pharmacogenetics partnership with Abbott Labs; and Cell Genesys sold its San Diego manufacturing facility, complete with employees, to Genzyme for $3.2 million. The Centient Biotech 200™ scored another new high, gaining 9 points at 4032.32, a rise of .21%. More details...
